Phase I Clinical Study of Combination Therapy with Eribulin and Capecitabine in Patients with Progressive Recurring Breast Cancer(JBCRG-18Cape)

Trial Profile

Phase I Clinical Study of Combination Therapy with Eribulin and Capecitabine in Patients with Progressive Recurring Breast Cancer(JBCRG-18Cape)

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jul 2015

At a glance

  • Drugs Capecitabine (Primary) ; Eribulin (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Jul 2015 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
    • 25 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
    • 30 Dec 2013 Planned number of patients changed from 6 to 9 as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top